Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google's AI R&D division DeepMind, has announced strategic partnerships with Eli Lilly And Co (NYSE:LLY) and ...

Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years. Demis Hassabis is at the helm of both Isomorphic and ...

Alphabet’s drug discovery arm, Isomorphic Labs, is preparing to enter a new chapter in its ambitious efforts to reshape medicine through artificial intelligence, with its first human clinical trials ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led the ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with ...

Simply sign up to the Artificial intelligence myFT Digest -- delivered directly to your inbox. Alphabet-owned Isomorphic Labs is ramping up its operations by poaching pharmaceutical talent and opening ...

Just more than two years after launching within Alphabet, Isomorphic has inked two large pharma deals with Eli Lilly and Novartis with nearly $3 billion in combined deal value. The two separate pacts ...